Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Study of LY2189265 Monotherapy Compared to Placebo and Liraglutide in Patients With Type 2 Diabetes Mellitus

Next Previous
X
Search
Trial Profile

A Phase 3 Study of LY2189265 Monotherapy Compared to Placebo and Liraglutide in Patients With Type 2 Diabetes Mellitus

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dulaglutide (Primary) ; Liraglutide
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Sponsors Eli Lilly and Company

    • Most Recent Events

    • 01 Feb 2018 Results of post hoc subgroup analysis assessing dulaglutide efficacy by baseline beta cell function (low, medium, and high values of fasting C-peptide, C-peptide index, and secretory units of islets in transplantation (SUIT) index) in Japanese patients published in the Diabetes Therapy
    • 06 Jun 2015 Results published in an Eli Lilly Media Release.
    • 06 Jun 2015 Primary endpoint has been met. (Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks) as per an Eli Lilly media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top